![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BARX2 |
Gene summary for BARX2 |
![]() |
Gene information | Species | Human | Gene symbol | BARX2 | Gene ID | 8538 |
Gene name | BARX homeobox 2 | |
Gene Alias | BARX2 | |
Cytomap | 11q24.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9UMQ3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8538 | BARX2 | LZE20T | Human | Esophagus | ESCC | 2.34e-03 | -1.56e-01 | 0.0662 |
8538 | BARX2 | P1T-E | Human | Esophagus | ESCC | 6.98e-03 | 1.01e-01 | 0.0875 |
8538 | BARX2 | P2T-E | Human | Esophagus | ESCC | 1.59e-06 | -2.31e-01 | 0.1177 |
8538 | BARX2 | P5T-E | Human | Esophagus | ESCC | 1.62e-08 | -1.53e-01 | 0.1327 |
8538 | BARX2 | P8T-E | Human | Esophagus | ESCC | 2.43e-05 | -2.52e-01 | 0.0889 |
8538 | BARX2 | P9T-E | Human | Esophagus | ESCC | 8.61e-03 | -2.64e-01 | 0.1131 |
8538 | BARX2 | P10T-E | Human | Esophagus | ESCC | 3.97e-04 | -2.64e-01 | 0.116 |
8538 | BARX2 | P12T-E | Human | Esophagus | ESCC | 1.68e-05 | -2.47e-01 | 0.1122 |
8538 | BARX2 | P16T-E | Human | Esophagus | ESCC | 8.40e-04 | -2.50e-01 | 0.1153 |
8538 | BARX2 | P20T-E | Human | Esophagus | ESCC | 1.13e-10 | -1.95e-02 | 0.1124 |
8538 | BARX2 | P21T-E | Human | Esophagus | ESCC | 4.31e-08 | -4.25e-02 | 0.1617 |
8538 | BARX2 | P22T-E | Human | Esophagus | ESCC | 3.73e-12 | -1.49e-01 | 0.1236 |
8538 | BARX2 | P23T-E | Human | Esophagus | ESCC | 4.00e-05 | 7.30e-02 | 0.108 |
8538 | BARX2 | P24T-E | Human | Esophagus | ESCC | 1.92e-04 | -2.10e-01 | 0.1287 |
8538 | BARX2 | P26T-E | Human | Esophagus | ESCC | 3.81e-06 | -2.37e-01 | 0.1276 |
8538 | BARX2 | P27T-E | Human | Esophagus | ESCC | 5.67e-04 | -1.74e-01 | 0.1055 |
8538 | BARX2 | P28T-E | Human | Esophagus | ESCC | 1.49e-05 | -2.34e-01 | 0.1149 |
8538 | BARX2 | P31T-E | Human | Esophagus | ESCC | 4.02e-02 | -1.16e-01 | 0.1251 |
8538 | BARX2 | P32T-E | Human | Esophagus | ESCC | 1.56e-05 | -2.59e-01 | 0.1666 |
8538 | BARX2 | P37T-E | Human | Esophagus | ESCC | 3.29e-04 | -2.36e-01 | 0.1371 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
GO:00512161 | Esophagus | ESCC | cartilage development | 103/8552 | 190/18723 | 1.08e-02 | 3.67e-02 | 103 |
GO:00426928 | Skin | AK | muscle cell differentiation | 64/1910 | 384/18723 | 5.51e-05 | 8.38e-04 | 64 |
GO:00614483 | Skin | AK | connective tissue development | 40/1910 | 252/18723 | 3.17e-03 | 1.95e-02 | 40 |
GO:00512162 | Skin | AK | cartilage development | 31/1910 | 190/18723 | 5.79e-03 | 3.14e-02 | 31 |
GO:00511468 | Skin | AK | striated muscle cell differentiation | 42/1910 | 283/18723 | 8.46e-03 | 4.19e-02 | 42 |
GO:004269215 | Skin | SCCIS | muscle cell differentiation | 37/919 | 384/18723 | 7.38e-05 | 1.71e-03 | 37 |
GO:005114616 | Skin | SCCIS | striated muscle cell differentiation | 25/919 | 283/18723 | 3.38e-03 | 3.01e-02 | 25 |
GO:005121611 | Skin | SCCIS | cartilage development | 18/919 | 190/18723 | 5.86e-03 | 4.52e-02 | 18 |
GO:006144811 | Skin | SCCIS | connective tissue development | 22/919 | 252/18723 | 6.57e-03 | 4.89e-02 | 22 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
BARX2 | TRANS | Cervix | Healthy | LY6D,CRABP2,KRT13, etc. | 2.62e-01 | ![]() |
BARX2 | IMENT | Colorectum | Healthy | ZNF622,SEMA3C,CA13, etc. | 3.12e-01 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BARX2 | SNV | Missense_Mutation | c.424N>A | p.Glu142Lys | p.E142K | Q9UMQ3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
BARX2 | SNV | Missense_Mutation | c.424G>A | p.Glu142Lys | p.E142K | Q9UMQ3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
BARX2 | SNV | Missense_Mutation | rs755171720 | c.754N>T | p.Arg252Cys | p.R252C | Q9UMQ3 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-B5-A11J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BARX2 | SNV | Missense_Mutation | c.120G>T | p.Glu40Asp | p.E40D | Q9UMQ3 | protein_coding | tolerated(0.07) | benign(0.174) | TCGA-BS-A0TC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BARX2 | SNV | Missense_Mutation | rs769021373 | c.616N>T | p.Arg206Cys | p.R206C | Q9UMQ3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BARX2 | SNV | Missense_Mutation | novel | c.506C>A | p.Ser169Tyr | p.S169Y | Q9UMQ3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
BARX2 | SNV | Missense_Mutation | novel | c.344C>A | p.Ala115Asp | p.A115D | Q9UMQ3 | protein_coding | tolerated(0.17) | benign(0.05) | TCGA-DD-AADR-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
BARX2 | SNV | Missense_Mutation | novel | c.648N>T | p.Glu216Asp | p.E216D | Q9UMQ3 | protein_coding | tolerated(0.09) | probably_damaging(0.978) | TCGA-55-1592-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
BARX2 | SNV | Missense_Mutation | c.763C>T | p.Pro255Ser | p.P255S | Q9UMQ3 | protein_coding | tolerated_low_confidence(0.3) | benign(0.001) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
BARX2 | SNV | Missense_Mutation | novel | c.581N>T | p.Lys194Ile | p.K194I | Q9UMQ3 | protein_coding | deleterious(0) | possibly_damaging(0.786) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |